Help patients with primary immunodeficiency to ensure that costs do not limit access to care.
Some commercial health insurance policies are now moving vital medications (mostly biologics such as immunoglobulin which primary immunodeficient patients rely on) into “specialty tiers” that utilize high patient cost-sharing methods.
H.R. 460, the Patients’ Access to Treatments Act seeks to restrain high out-of-pocket costs for specialty medications like immunoglobulin. This bipartisan legislation will help ensure patients, with chronic, disability and life threatening conditions to access the treatments they need. It would limit out-of-pocket costs for medications in a specialty drug tier (typically Tier IV or higher) to the dollar amount applicable to the drugs in a non-preferred brand drug tier.
Visit the Immune Deficiency Foundation’s page for more information.